Galip Can Uyar Highlighted the JCOG1314 (MIRACLE) Study on Metastatic Esophageal Cancer
Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on LinkedIn about the JCOG1314 (MIRACLE) Study by Takahiro Tsushima et al., published in JCO:
“New Phase III Trial in JCO Oncology Advances
The JCOG1314 (MIRACLE) study evaluated whether adding biweekly docetaxel (bDCF) to cisplatin–fluorouracil (CF) could improve outcomes in metastatic esophageal cancer.
Key Findings:
- Median OS: 16.2 vs 14.8 months (bDCF vs CF, HR 0.90; p=0.23) – no OS benefit
- Median PFS: 6.0 vs 5.2 months (HR 0.68) – significant improvement
- Toxicities: higher neutropenia & anorexia with bDCF, but no treatment-related deaths
- Exploratory subgroup: patients with high NLR (>5) derived clear OS and PFS benefit
Take-home: Triplet chemotherapy (bDCF) is not superior to CF in unselected patients, but inflammatory biomarkers such as NLR may guide future treatment intensification strategies.”
Title: First-Line Docetaxel Once Every 2 Weeks With Cisplatin Plus Fluorouracil for Metastatic Esophageal Cancer: A Multicenter, Randomized Controlled Phase III Study (JCOG1314, MIRACLE)
Journal: JCO
Authors: Takahiro Tsushima, Shuichi Hironaka, Yasuhiro Tsubosa, Ryunosuke Machida, Ken Kato, Shigenori Kadowaki, Motoo Nomura, Hiroki Hara, Yuko Kitagawa, Kazuo Koyanagi, Takeshi Kajiwara, Naoki Takegawa, Hisahiro Matsubara, Masaaki Iwatsuki, Yasue Kimura, Keijiro Sugimura, Hiroko Hasegawa, Takashi Kojima, Satoru Matsuda, Keita Sasaki, Hiroya Takeuchi
More posts featuring Galip Can Uyar on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023